PRESIDENT OF LEADING SOUTH KOREAN BIOPHARMACEUTICAL COMPANY GREEN CROSS HOLDINGS JOINS STEMEDICA’S BOARD OF DIRECTORS
Stemedica welcomes Byung-Geon “BG” Rhee, Ph.D., President of Green Cross Holdings, a South Korean biopharmaceutical company, to its board of directors.
STEMEDICA APPOINTS NIH CENTER FOR REGENERATIVE MEDICINE FOUNDING DIRECTOR DR. MAHENDRA RAO TO ITS SCIENTIFIC AND MEDICAL ADVISORY BOARD
Stemedica welcomes to its Scientific and Medical Advisory Board prominent stem cell and regenerative medicine expert Dr. Mahendra Rao, M.D., Ph.D.
DRIVEN BY 30 YEARS OF STEM CELL RESEARCH & SCIENTIFIC ADVANCEMENT
Transforming Medicine for the 21st Century
Stemedica Cell Technologies, Inc., is transforming regenerative medicine through the development and manufacturing of adult ischemic-tolerant stem cell products and biological compounds. Our technology has led us to breakthroughs that are changing medicine and improving life globally. As one of the few companies licensed and approved for clinical grade manufacturing and trial applications by regulatory agencies worldwide, our focus is on producing the best-in-class products available today.
Watch a short informative video about our company and the unique technological advantages of our proprietary adult stem cells.
Stemedica Cell Technologies and Smart Living, a subsidiary of Smart Global, a $2 billion (USD) globally diversified conglomerate, are pleased to announce an international educational collaboration.
Applying stem-cell technology for cardiovascular indications is not just an idea anymore.
CardioCell is currently in clinical trials using stem cells to develop highly effective, “off-the-shelf” therapeutic products for cardiovascular indication.
Further information >>